about
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.Prediction of the response of colorectal cancer to systemic therapy.Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.What can the molecular pathologist offer for optimal decision making?Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables.RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016).Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification.KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.Failure to validate toxicity and outcome biomarkers from the FFCD 2000-05 trial in the MRC CR08 FOCUS trial.Left and right sided large bowel cancerKRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancerResponseResults of the UK NEQAS for Molecular Genetics reference sample analysisExploring outcomes of RAS-mutant (RAS mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs)Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trialTargeted next generation sequencing reveals a common genetic pathway for colorectal cancers with chromosomal instability and those with microsatellite and chromosome stability
P50
Q27853335-46A75D76-E259-434F-B59F-23A79CF93727Q34362289-B079EE80-71DB-4649-BD81-3811216645B0Q34569963-A861635B-3140-4FC0-B0DB-017C32387407Q35921785-49734D38-07DF-4C33-8FF7-62E1C9027EA5Q36475718-87069440-7F7C-458D-BA69-648B082202A6Q36977022-D1E59EFB-1801-41D0-9888-0FF7753E1F9BQ37600051-14C30295-3662-4637-B1D0-8C0AE6A122B1Q37799917-F711605D-AFB3-4E4E-AC93-5BAFD9AB7B2DQ38678370-BD0A0E47-5C2A-434F-B0E8-98152B6A4122Q38707761-ED1D3823-C2A8-4CD4-8038-7D3364E450DCQ38754724-B2FD4522-0EC0-4008-AFC9-B0C4E38488C9Q39225749-3ADB3E61-5D8F-4E46-B611-AD04F622CC14Q41959760-AA7F68B1-C3C6-4035-991C-40F306192BC0Q42722558-9757B52C-8ACA-45CA-B2E2-B1E21B2CD411Q42777241-17C24C4A-ABE3-4A82-9CD6-DC5FB65D91A4Q43250046-42D12C6F-AD80-438F-8D69-8FF18E6A2840Q43254499-22E336F5-0BB4-4C5E-9A00-7C9EEDC9861EQ44547612-497FE4A2-2212-41A0-929F-99E6515E8E61Q46570394-B091AC0D-D5DD-40CC-94F4-2F84ACBDA743Q47707557-5DBFE91B-E624-40A7-BA69-E19B775F16E0Q48943519-0371302C-8AE4-4F05-89A0-2975242E869BQ52845850-6C50D599-CACD-4AB3-9B5E-50CC9A5D187DQ52846071-2F884D7D-8E75-4C27-8C7E-56615793352BQ56436698-FD66D07A-2FC8-426D-9E29-F4FE2AC842E3Q56441204-E7C77143-8F8D-405A-BC3E-848E5DF11AB4Q58417919-C472847A-5F18-4FF4-AD37-3959A95F7EB1Q61308298-F071E606-10CD-40E3-B254-624ED87DCF99Q91813079-5EAA419A-7684-4313-A22F-32BCE057CB0AQ92462215-8176F702-6C20-45BA-BA83-D015E0FC773C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-ca
researcher
@en-gb
ricercatrice
@it
հետազոտող
@hy
name
Susan D Richman
@ast
Susan D Richman
@cy
Susan D Richman
@en
Susan D Richman
@en-gb
Susan D Richman
@es
Susan D Richman
@nl
Susan D Richman
@sl
type
label
Susan D Richman
@ast
Susan D Richman
@cy
Susan D Richman
@en
Susan D Richman
@en-gb
Susan D Richman
@es
Susan D Richman
@nl
Susan D Richman
@sl
prefLabel
Susan D Richman
@ast
Susan D Richman
@cy
Susan D Richman
@en
Susan D Richman
@en-gb
Susan D Richman
@es
Susan D Richman
@nl
Susan D Richman
@sl
P106
P1153
36973502600
P21
P214
177148207842700341331
P31
P496
0000-0003-3993-5041
P6178
01043462267.33
P734
P735
P7859
viaf-177148207842700341331